Show simple item record

dc.contributor.authorEl-Taji, OMSen
dc.contributor.authorAlam, Sen
dc.contributor.authorHussain, SAen
dc.date.accessioned2018-01-22T11:17:41Z
dc.date.available2018-01-22T11:17:41Z
dc.date.issued2016-03en
dc.identifier.urihttp://hdl.handle.net/10026.1/10632
dc.description.abstract

OPINION STATEMENT: Organ preservation has been increasingly utilised in the management of muscle-invasive bladder cancer. Multiple bladder preservation options exist, although the approach of maximal TURBT performed along with chemoradiation is the most favoured. Phase III trials have shown superiority of chemoradiotherapy compared to radiotherapy alone. Concurrent chemoradiotherapy gives local control outcomes comparable to those of radical surgery, but seemingly more superior when considering quality of life. Bladder-preserving techniques represent an alternative for patients who are unfit for cystectomy or decline major surgical intervention; however, these patients will need lifelong rigorous surveillance. It is important to emphasise to the patients opting for organ preservation the need for lifelong bladder surveillance as risk of recurrence remains even years after radical chemoradiotherapy treatment. No randomised control trials have yet directly compared radical cystectomy with bladder-preserving chemoradiation, leaving the age-old question of superiority of one modality over another unanswered. Radical cystectomy and chemoradiation, however, must be seen as complimentary treatments rather than competing treatments. Meticulous patient selection is vital in treatment modality selection with the success of recent trials within the field of bladder preservation only being possible through this application of meticulous selection criteria compared to previous decades. A multidisciplinary approach with radiation oncologists, medical oncologists, and urologists is needed to closely monitor patients who undergo bladder preservation in order to optimise outcomes.

en
dc.format.extent15 - ?en
dc.languageengen
dc.language.isoengen
dc.subjectBladder canceren
dc.subjectBladder preservationen
dc.subjectBladder sparingen
dc.subjectChemoradiationen
dc.subjectMuscle-invasiveen
dc.subjectOrgan preservationen
dc.subjectChemoradiotherapyen
dc.subjectCombined Modality Therapyen
dc.subjectCystectomyen
dc.subjectHumansen
dc.subjectNeoplasm Invasivenessen
dc.subjectNeoplasm Recurrence, Localen
dc.subjectPatient Selectionen
dc.subjectUrinary Bladderen
dc.subjectUrinary Bladder Neoplasmsen
dc.titleBladder Sparing Approaches for Muscle-Invasive Bladder Cancers.en
dc.typeJournal Article
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/26942590en
plymouth.issue3en
plymouth.volume17en
plymouth.publication-statusPublisheden
plymouth.journalCurr Treat Options Oncolen
dc.identifier.doi10.1007/s11864-016-0390-8en
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine/UoA01 Clinical Medicine
dc.publisher.placeUnited Statesen
dc.identifier.eissn1534-6277en
dc.rights.embargoperiodNot knownen
rioxxterms.versionofrecord10.1007/s11864-016-0390-8en
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.typeJournal Article/Reviewen


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV